Actively Recruiting
Pressure Wire Guidance for Infrapopliteal Artery Interventions
Led by Yonsei University · Updated on 2025-12-02
100
Participants Needed
1
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
"• A prospective, single-center randomized controlled comparison trial. * A total of 100 patients with symptoms of chronic limb-threatening ischemia (Rutherford category 5) undergoing endovascular treatment for anterior tibial artery or posterior tibial artery lesions will be included if they meet the inclusion criteria and do not meet any exclusion criteria. * Patients will be randomized in a 1:1 open-label manner either to the pressure wire-guided group or the angiography-guided group. * Patients will be treated with balloon angioplasty for anetrior tibial artery or posterior tibial artery lesions. * In the angiography-guided group, balloon angioplasty will be performed to achieve an optimal procedural result, as determined by angiography. Optimal results are defined as antegrade blood flow without residual stenosis \>50% or flow-limiting dissection. * In the Pressure Wire-guided gorup, balloon angioplasty will be performed to obtain optimal procedural result based on both angiography and a pressure gradient over the target lesion. Optimal pressure gradient is less than 10 mmHg by measurement using a Pressure Wire. * The primary efficacy endpoint is defined by attaiment of skin perfusion pressure ≥50 mmHg within 1-3 days after the index procedure. * Patients will be followed at 1, 3, and 6 months after the procdure to assess wound healing status, and clinical events."
CONDITIONS
Official Title
Pressure Wire Guidance for Infrapopliteal Artery Interventions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with chronic limb threatening ischemia (Rutherford 5)
- Anterior tibial artery or posterior tibial artery lesions �3E= 10 cm
- Age �3E=19 years
You will not qualify if you...
- Acute limb ischemia
- Contraindication to antiplatelet or anticoagulation agents including thrombocytopenia (platelet <100,000/uL)
- Previous cerebral hemorrhage, gastrointestinal bleeding, or other bleeding risks within 6 months
- Pregnant women or women with potential childbearing
- Life expectancy less than 1 year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Division of Cardiology, Severance Cardiovascular hospital Department of Internal Medicine, Yonsei University College of Medicine
Seoul, South Korea
Actively Recruiting
Research Team
Y
Young-Guk Ko, MD. Division of Cardiology
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here